Conversely, a significant increase in PD‐L1 expression levels on the surface of NSCLC cells was observed following treatment with a commercial HLA‐G blocking/neutralizing antibody (mAb 87G) or when cocultured with PBMCs in combination with mAb 87G (Figure 1H,J). This evidence concerns the gene HLA-G and non-small cell lung carcinoma.